Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network

PLoS Genetics

Volumn 8, Issue 6, 2012, Pages

  Pylkäs, Katri ^a   Vuorela, Mikko ^a   Otsukka, Meeri ^a   Kallioniemi, Anne ^b   Jukkola Vuorinen, Arja ^a   Winqvist, Robert ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRADIOL; ESTROGEN; GENOMIC DNA; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BLM GENE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASP3 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; DCLRE1C GENE; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ESR2 GENE; FAMILIAL CANCER; FEMALE; GENE; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; RECQL4 GENE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; AGED; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84864040193     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002734     Document Type: Article

References (54)

1. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from sweden, denmark, and finland. N Engl J Med 343: 78-85.
2. Stratton MR, Rahman N, (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40: 17-22.
3. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504-507.
4. International Schizophrenia Consortium (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
5. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539-543.
6. Craddock N, Hurles ME, Cardin N, Pearson RD, et al. Wellcome Trust Case Control Consortium (2010) Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 464: 713-720.
7. Venkitaraman AR, (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
8. Tokino T, Nakamura Y, (2000) The role of p53-target genes in human cancer. Crit Rev Oncol Hematol 33: 1-6.
9. Keniry M, Parsons R, (2008) The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485.
10. Fodde R, Smits R, (2002) Cancer biology. A matter of dosage. Science 298: 761-763.
11. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, et al. (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14: 927-939.
12. Abe T, Yoshimura A, Hosono Y, Tada S, Seki M, et al. (2011) The N-terminal region of RECQL4 lacking the helicase domain is both essential and sufficient for the viability of vertebrate cells. role of the N-terminal region of RECQL4 in cells. Biochim Biophys Acta 1813: 473-479.
13. Ma Y, Pannicke U, Schwarz K, Lieber MR, (2002) Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108: 781-794.
14. Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, et al. (1995) The bloom's syndrome gene product is homologous to RecQ helicases. Cell 83: 655-666.
15. Kitao S, Shimamoto A, Goto M, Miller RW, Smithson WA, et al. (1999) Mutations in RECQL4 cause a subset of cases of rothmund-thomson syndrome. Nat Genet 22: 82-84.
16. Moshous D, Pannetier C, Chasseval Rd R, Deist Fl F, Cavazzana-Calvo M, et al. (2003) Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in artemis. J Clin Invest 111: 381-387.
17. Pannicke U, Honig M, Schulze I, Rohr J, Heinz GA, et al. (2010) The most frequent DCLRE1C (ARTEMIS) mutations are based on homologous recombination events. Hum Mutat 31: 197-207.
18. Gavvovidis I, Pohlmann C, Marchal JA, Stumm M, Yamashita D, et al. (2010) MCPH1 patient cells exhibit delayed release from DNA damage-induced G2/M checkpoint arrest. Cell Cycle 9: 4893-4899.
19. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
20. Menashe I, Maeder D, Garcia-Closas M, Figueroa JD, Bhattacharjee S, et al. (2010) Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res 70: 4453-4459.
21. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97: 4262-4266.
22. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
23. Sengupta S, Shimamoto A, Koshiji M, Pedeux R, Rusin M, et al. (2005) Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 24: 1738-1748.
24. Sengupta S, Linke SP, Pedeux R, Yang Q, Farnsworth J, et al. (2003) BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J 22: 1210-1222.
25. Miyazaki K, Ozaki T, Kato C, Hanamoto T, Fujita T, et al. (2003) A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem Biophys Res Commun 308: 106-113.
26. Lunardi A, Di Minin G, Provero P, Dal Ferro M, Carotti M, et al. (2010) A genome-scale protein interaction profile of drosophila p53 uncovers additional nodes of the human p53 network. Proc Natl Acad Sci U S A 107: 6322-6327.
27. Cummings BS, Schnellmann RG, (2002) Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and-independent pathways. J Pharmacol Exp Ther 302: 8-17.
28. Anderson E, (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4: 197-201.
29. Barros RP, Gustafsson JA, (2011) Estrogen receptors and the metabolic network. Cell Metab 14: 289-299.
30. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A, (2009) Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 69: 5793-5800.
31. Thompson CJ, Tam NN, Joyce JM, Leav I, Ho SM, (2002) Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in noble rats and response to the antiestrogen ICI 182,780. Endocrinology 143: 2093-2105.
32. Childs EW, Tharakan B, Hunter FA, Smythe WR, (2010) 17beta-estradiol mediated protection against vascular leak after hemorrhagic shock: Role of estrogen receptors and apoptotic signaling. Shock 34: 229-235.
33. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, et al. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437-1441.
34. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, et al. (2004) Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 10: 2082-2089.
35. Xie D, Gore C, Liu J, Pong RC, Mason R, et al. (2010) Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 107: 2485-2490.
36. Hengartner MO, (2000) The biochemistry of apoptosis. Nature 407: 770-776.
37. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, et al. (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39: 352-358.
38. Zhan Q, Jin S, Ng B, Plisket J, Shangary S, et al. (2002) Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis. Oncogene 21: 5335-5345.
39. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, et al. (1998) The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243: 122-126.
40. Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, et al. (2005) Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat 94: 145-152.
41. Gold B, Kalush F, Bergeron J, Scott K, Mitra N, et al. (2004) Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 64: 8891-8900.
42. Speirs V, Kerin MJ, (2000) Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 87: 405-409.
43. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, et al. (2004) Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A 101: 17126-17131.
44. Castets F, Bartoli M, Barnier JV, Baillat G, Salin P, et al. (1996) A novel calmodulin-binding protein, belonging to the WD-repeat family, is localized in dendrites of a subset of CNS neurons. J Cell Biol 134: 1051-1062.
45. Lu Q, Surks HK, Ebling H, Baur WE, Brown D, et al. (2003) Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A. J Biol Chem 278: 4639-4645.
46. Guengerich FP, (2001) Forging the links between metabolism and carcinogenesis. Mutat Res 488: 195-209.
47. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, et al. (2009) CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 115: 391-396.
48. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK, (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28: 328-332.
49. Larsson SC, Mantzoros CS, Wolk A, (2007) Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 121: 856-862.
50. Xue F, Michels KB, (2007) Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. Am J Clin Nutr 86: s823-35.
51. Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, et al. (2012) Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 14: R24.
52. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, et al. (2007) A recurrent mutation in PALB2 in finnish cancer families. Nature 446: 316-319.
53. Brunet J, (2010) Hereditary breast cancer and genetic counseling in young women. Breast Cancer Res Treat 123 (Suppl 1): 7-9.
54. Kuiper RP, Ligtenberg MJ, Hoogerbrugge N, Geurts van Kessel A, (2010) Germline copy number variation and cancer risk. Curr Opin Genet Dev 20: 282-289.